Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant
therapy guideline for resected non–small-cell lung cancers. Methods ASCO convened an …

Cancer is among the leading causes of mortality and morbidity worldwide. Among the
different types of cancers, lung cancer is considered to be the leading cause of death related …

Rationale: Subsets of patients with early-stage lung adenocarcinoma (LUAD) have a poor
post-surgical course after curative surgery. However, biomarkers stratifying this high-risk …

Objective This study aimed to construct a nomogram to effectively predict the overall survival
(OS) of patients with stage IB non-small-cell lung cancer (NSCLC). Methods In total, 5513 …

Rationale: The current tumour-node-metastasis (TNM) staging system is insufficient for
precise treatment decision-making and accurate survival prediction for patients with stage I …

Importance Tumor size larger than 4 cm is accepted as an indication for adjuvant
chemotherapy in patients with node-negative non–small cell lung cancer (NSCLC) …

Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy,
resulting in considerable undertreatment or overtreatment. New insights into the role of …

Molecularly targeted and immunotherapies have improved the care of patients with lung
cancers. These successes have rallied calls to replace or avoid chemotherapy. Yet, even in …

Stereotactic body radiation therapy (SBRT) is the treatment of choice for medically
inoperable patients with early stage non-small cell lung cancer (NSCLC). A literature search …

Background This study aimed to investigate the efficacy of adjuvant chemotherapy for
pathologic stage I non-small cell lung cancer (NSCLC) with high risk for recurrence …